Development of novel benznidazole formulations: Physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease

被引:36
|
作者
Palmeiro-Roldan, Ricardo [1 ]
Fonseca-Berzal, Cristina [2 ,3 ,4 ]
Gomez-Barrio, Alicia [2 ,3 ,4 ]
Aran, Vicente J. [2 ,3 ,5 ]
Escario, Jose A. [2 ,3 ,4 ]
Torrado-Duran, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
机构
[1] Univ Complutense Madrid, Fac Pharm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] UCM UPM, Madrid, Spain
[3] CSIC, Madrid, Spain
[4] Univ Complutense Madrid, Fac Pharm, Dept Parasitol, E-28040 Madrid, Spain
[5] CSIC, Inst Quim Med, E-28006 Madrid, Spain
关键词
Benznidazole; Solid dispersions; Physicochemical characterization; Dissolution study; Trypanocidal activity; SOLID-STATE CHARACTERIZATION; CONTROLLED-RELEASE; BILE-SALTS; DISPERSION; DISSOLUTION; DRUG; ABSORPTION; BEHAVIOR; MIXTURE;
D O I
10.1016/j.ijpharm.2014.06.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This work aims to develop novel benznidazole (BZN) solid dispersions (SD) to improve its solubility and bioavailability properties. Low-substituted hydroxypropylcellulose (L-HPC) and sodium deoxycholate (NaDC) were evaluated as carriers. BZN solid dispersions containing different ratios of carrier were prepared by a freeze-drying process and characterized by SEM, powder X-ray diffraction (XRD), differential scanning calorimetry (DSC) and dissolution studies. The reduced BNZ crystallinity in the new formulations was confirmed by XRD, and supported by DSC. BNZ:L-HPC solid dispersion at a 1:3 ratio (w/w) (SD-1:3 L-HPC) improved the BNZ dissolution rate (85% at 5 min) in comparison with BNZ raw material (23% at 5 min). However, NaDC formulations showed a prolonged release (24% at 30 min for SD-1:3 NaDC), due to the formation of a sustained release matrix in acidic medium. In vivo studies performed in a murine model of Chagas disease showed that the formulation achieving the highest parasitemia suppression at a low dose of 25 mg/kg/day after five days of treatment was SD-1:3 L-HPC (60% of parasitemia suppression versus 33% of suppression exerted by BNZ), suggesting that BNZ:L-HPC systems enhance the bioavailability of the drug. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:110 / 117
页数:8
相关论文
共 50 条
  • [1] Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole
    Pavan, Tycha Bianca Sabaini
    de Almeida, Eros Antonio
    de Lima, Rodrigo Goncalves
    Wanderley, Jamiro da Silva
    Martins, Luiz Claudio
    Costa, Sandra Cecilia Botelho
    Marcon, Glaucia Elisete Barbosa
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2023, 16 (12) : 565 - 572
  • [2] Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks
    Leonardi, Dario
    Salomon, Claudiol.
    Lamas, Maria C.
    Olivieri, Alejandro C.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 367 (1-2) : 140 - 147
  • [3] An evaluation of benznidazole as a Chagas disease therapeutic
    Caldas, Ivo S.
    Santos, Elda G.
    Novaes, Romulo D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1797 - 1807
  • [4] Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease
    Maximiano, Flavia Pires
    de Paula, Livia Maria
    Figueiredo, Vivian Paulino
    de Andrade, Isabel Mayer
    Talvani, Andre
    Sa-Barreto, Livia C.
    Bahia, Maria Terezinha
    Cunha-Filho, Marcilio S. S.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, 78 (03) : 377 - 384
  • [5] Efficacy of the Benznidazole plus Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
    Eduardo Echeverria, Luis
    Isabel Gonzalez, Clara
    Mantilla Hernandez, Julio Cesar
    Lucia Diaz, Martha
    Eduardo Nieto, Javier
    Alberto Lopez-Romero, Luis
    David Rivera, Julian
    Uriel Suarez, Edwin
    Gomez Ochoa, Sergio Alejandro
    Rojas, Lyda Z.
    Morillo, Carlos A.
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2020, 53
  • [6] A Preformulation Study of a New Medicine for Chagas Disease Treatment: Physicochemical Characterization, Thermal Stability, and Compatibility of Benznidazole
    José Lamartine Soares-Sobrinho
    Mônica Felts de La Roca Soares
    Pablo Queiroz Lopes
    Lidiane Pinto Correia
    Fábio Santos de Souza
    Rui Oliveira Macêdo
    Pedro José Rolim-Neto
    AAPS PharmSciTech, 2010, 11 : 1391 - 1396
  • [7] A Preformulation Study of a New Medicine for Chagas Disease Treatment: Physicochemical Characterization, Thermal Stability, and Compatibility of Benznidazole
    Soares-Sobrinho, Jose Lamartine
    de La Roca Soares, Monica Felts
    Lopes, Pablo Queiroz
    Correia, Lidiane Pinto
    de Souza, Fabio Santos
    Macedo, Rui Oliveira
    Rolim-Neto, Pedro Jose
    AAPS PHARMSCITECH, 2010, 11 (03): : 1391 - 1396
  • [8] Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease
    Mazzeti, Ana Lia
    Goncalves, Karolina Ribeiro
    Boasquivis, Patricia Ferreira
    Bahia, Maria Terezinha
    Mosqueira, Vanessa Carla Furtado
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2025, 10 (02)
  • [9] Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?
    Seremeta, Katia P.
    Arrua, Eva C.
    Okulik, Nora B.
    Salomon, Claudio J.
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2019, 177 : 169 - 177
  • [10] Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
    Lucas Gontijo, Maria Katarine Costa
    Benevides da Silva de Arruda, Hilda Maria
    Noronha, Elza Ferreira
    de Toledo, Maria Ines
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2020, 53